{"filing":{"accession_number":"0001062993-26-005431","cik":"0002066836","ticker":"CNXU","company_name":"Conexeu Sciences Inc.","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-15","primary_document":"form8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2066836/000106299326005431/form8k.htm"},"events":[{"id":36452,"run_id":33610,"accession_number":"0001062993-26-005431","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This Item 3.02 disclosure describes multiple unregistered equity issuances by Conexeu Sciences between September 14 and October 15, 2026, totaling approximately 3.4 million shares and units that exceeded 5% of outstanding shares, triggering mandatory 8-K disclosure. The principal transaction is a $3.999 million private placement of 1,333,333 units (each comprising one share and one warrant) to accredited investors on October 15, 2026, relying on Regulation D Rule 506(b) and Regulation S exemptions. Additional issuances include consultant equity grants and warrant exercises. This is a classic dilutive private placement raising capital through unregistered securities, material to investors assessing ownership dilution and capital structure.","company_name":"Conexeu Sciences Inc.","ticker":"CNXU","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40869,"accession_number":"0001062993-26-005431","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This Item 3.02 disclosure describes multiple unregistered equity issuances by Conexeu Sciences between September 14 and October 15, 2026, totaling approximately 3.4 million shares and units that exceeded 5% of outstanding shares, triggering mandatory 8-K disclosure. The principal transaction is a $3.999 million private placement of 1,333,333 units (each comprising one share and one warrant) to accredited investors on October 15, 2026, relying on Regulation D Rule 506(b) and Regulation S exemptions. Additional issuances include consultant equity grants and warrant exercises. This is a classic dilutive private placement raising capital through unregistered securities, material to investors assessing ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:31:56.876197+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40869,"accession_number":"0001062993-26-005431","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This Item 3.02 disclosure describes multiple unregistered equity issuances by Conexeu Sciences between September 14 and October 15, 2026, totaling approximately 3.4 million shares and units that exceeded 5% of outstanding shares, triggering mandatory 8-K disclosure. The principal transaction is a $3.999 million private placement of 1,333,333 units (each comprising one share and one warrant) to accredited investors on October 15, 2026, relying on Regulation D Rule 506(b) and Regulation S exemptions. Additional issuances include consultant equity grants and warrant exercises. This is a classic dilutive private placement raising capital through unregistered securities, material to investors assessing ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:31:56.876197+00:00","company_name":"Conexeu Sciences Inc.","ticker":"CNXU","filing_date":"2026-10-20"}]}